Asset profile
Emestedastat · Xanamem
Small molecule
Evidence outlook · registrational
Alzheimer's Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2026-10.
NCT02727699: Randomized, triple-masked, placebo-controlled phase 2 in mild Alzheimer's dementia (185 participants). The co-primary cognition scores moved similarly in both arms and no statistical analysis is posted, so the primary outcome cannot be called from the registry record.
Also in development:Major Depressive Disorder · Phase 2
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.